Nov 19, 2019 Press Release for Alnylam
Alnylam Announces Second Annual Advocacy for Impact Grants Program
Nov 19, 2019
− Program Aims to Inspire Creative Patient Advocacy Solutions to Unique Challenges in Rare Disease Communities −
− Funding Will Support Unmet Needs in the ATTR Amyloidosis, Acute Hepatic Porphyria and Primary Hyperoxaluria Type 1 Communities –
“We were strongly encouraged by the number of applicants we received in the first year of the Advocacy for Impact grants program,” said
Advocacy for Impact grants will recognize and fund new projects, each in an amount up to
- Increase disease awareness and access to diagnosis
- Offer education to patients, families, caregivers, healthcare providers, and/or the public
- Improve patient care
To be eligible, patient advocacy groups must have charitable status and may only submit one proposal per year. Applications will be accepted via email to AdvocacyForImpact@alnylam.com from today through
In its first year of the program, Alnylam provided
“We held an immersive and engaging event that brought together all of those connected to the porphyrias, especially those under 30 years of age, who are often socially alienated by their condition,” said
Additional information about these recipients and their programs can be read here. Please visit the Alnylam Advocacy for Impact grants page for additional information about the application process.
About
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam’s first commercial RNAi therapeutic is ONPATTRO® (patisiran), approved in the U.S., EU,
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005112/en/
Source:
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
For Media Inquiries, please contact:
Christine Lindenboom
SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam